-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Ece+/CqCUXBcgeWc4nTb93gIrQHVrnf8qXu9KKf3p+twwRH4LPb6dYDwQjRsw+RD VjrpsJ7u+BprD5R8Fs5TQQ== 0001193125-03-018698.txt : 20030711 0001193125-03-018698.hdr.sgml : 20030711 20030711153015 ACCESSION NUMBER: 0001193125-03-018698 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20030709 ITEM INFORMATION: Financial statements and exhibits ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20030711 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VENTANA MEDICAL SYSTEMS INC CENTRAL INDEX KEY: 0000893160 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 942976937 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-20931 FILM NUMBER: 03783773 BUSINESS ADDRESS: STREET 1: 3865 N BUSINESS CENTER DRIVE CITY: TUCSON STATE: AZ ZIP: 85705 BUSINESS PHONE: 5208872155 MAIL ADDRESS: STREET 1: 3865 N BUSINESS CENTER DR CITY: TUCSON STATE: AZ ZIP: 85705 8-K 1 d8k.htm FORM 8-K Form 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported) July 9, 2003

 


 

VENTANA MEDICAL SYSTEMS, INC.

(Exact name of Registrant as specified in its charter)

 

State of Delaware   000-20931   94-2976937

(State or other jurisdiction of

incorporation or organization)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification Number)

 

1910 Innovation Park Drive

Tuscon, AZ 85737

(Address of principal executive offices)

 

(520) 887-2155

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 


 


Item 7.   Financial Statements and Exhibits

 

(c) Exhibits

 

ExhibitNo.

  

Description


99.1

   Press Release, dated as of July 9, 2003

 

Item 9.   Regulation FD Disclosure (pursuant to Item 12)

 

This information, furnished under “Item 9. Regulation FD Disclosure,” is intended to be furnished under “Item 12. Disclosure of Results of Operations and Financial Condition” in accordance with SEC Release No. 33-8216.

 

On July 9, 2003, Ventana Medical Systems, Inc. issued a press release announcing preliminary second quarter earnings results. A copy of the press release is attached as Exhibit 99.1.

 


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

VENTANA MEDICAL SYSTEMS, INC.

By:

 

/s/    NICHOLAS MALDEN        


   

Nicholas Malden

Vice President, Chief Financial Officer and Secretary

 

Date: July 9, 2003

 

 

 


EXHIBIT INDEX

 

Exhibit

  

Description


99.1   

Press release issued by Ventana Medical Systems, Inc. dated July 9, 2003

 

EX-99.1 3 dex991.htm PRESS RELEASE, DATED AS OF JULY 9, 2003 Press Release, dated as of July 9, 2003

EXHIBIT 99.1

 

[LOGO OF VENTANA]

         
Ventana Medical Systems, Inc.         Contact:
1910 Innovation Park Drive         Christopher M. Gleeson
Tucson, Arizona 85737         President and CEO
(520) 887-2155         (520) 229-3787

July 9, 2003

        Nick Malden
          Chief Financial Officer
          (520) 229-3857

 

VMSI Preliminary Results Substantially Exceed Expectations

 

Tucson, Ariz., Wednesday, July 9, 2003 – Ventana Medical Systems, Inc. (NASDAQ: VMSI), today announced preliminary results for the quarter ended June 30, 2003 indicating that earnings per share would be in a range of $0.17 - $0.20 on stronger than expected revenues. This exceeds the current consensus of $0.12 per share and the $0.03 earnings per share reported in the second quarter of last year.

 

Commenting on the quarter, Christopher Gleeson, President and CEO, said “placements of the BenchMark system have been ahead of expectations over the last six months driving strong consumable revenue growth, particularly in this last quarter and potentially impacting the remainder of 2003. We are evaluating our current projections and will discuss this subject in conjunction with our upcoming quarterly conference call”.

 

Second Quarter Conference Call

 

Ventana will release second quarter financial results on July 18, 2003 and host a conference call that same day at 10:00 a.m. EDT to discuss these results and 2003 full year projections. Call details will be the subject of a separate press release.

 

Ventana develops, manufactures and markets instrument/reagent systems that automate tissue preparation and slide staining in clinical histology and drug discovery laboratories worldwide. Ventana’s clinical systems are important tools used in the diagnosis and treatment of cancer and infectious diseases. Ventana’s drug discovery systems are used to accelerate the discovery of new drug targets and evaluate the safety of new drug compounds.

 

Any statements made about the company’s anticipated financial results are forward-looking statements subject to risks and uncertainties such as those described in Ventana’s Annual Report on Form 10-K for the year ended December 31, 2002. Actual results may differ materially from anticipated results.

 

Visit the Ventana Medical Systems, Inc. website at www.ventanamed.com

 

The Molecular Discovery Systems Division has its own website at www.ventanadiscovery.com

-----END PRIVACY-ENHANCED MESSAGE-----